Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate IRADIMED CORPORATION before investing.

In this article, we go over a few key elements for understanding IRADIMED CORPORATION’s stock price such as:

• IRADIMED CORPORATION’s current stock price and volume
• Why IRADIMED CORPORATION’s stock price changed recently
• Upgrades and downgrades for IRMD from analysts
• IRMD’s stock price momentum as measured by its relative strength

About IRADIMED CORPORATION (IRMD)

Before we jump into IRADIMED CORPORATION’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Want to learn more about IRADIMED CORPORATION’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about IRADIMED CORPORATION.

IRADIMED CORPORATION’s Stock Price as of Market Close

As of July 31, 2026, 2:15 PM, CST, IRADIMED CORPORATION’s stock price was $93.730.

IRADIMED CORPORATION is down 1.55% from its previous closing price of $95.210.

During the last market session, IRADIMED CORPORATION’s stock traded between $91.370 and $97.740. Currently, there are approximately 12.78 million shares outstanding for IRADIMED CORPORATION.

IRADIMED CORPORATION’s price-earnings (P/E) ratio is currently at 52.0, which is high compared to the Health Care Equipment & Supplies industry median of 30.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

IRADIMED CORPORATION Stock Price History

IRADIMED CORPORATION’s (IRMD) price is currently down 1.92% so far this month.

During the month of July, IRADIMED CORPORATION’s stock price has reached a high of $102.990 and a low of $90.830.

Over the last year, IRADIMED CORPORATION has hit prices as high as $107.900 and as low as $57.830. Year to date, IRADIMED CORPORATION’s stock is down 3.65%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused IRADIMED CORPORATION Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 30, 2026,, no analysts have changed their rating of IRADIMED CORPORATION’s stock over the last month.

Additionally, you'll want to evaluate IRADIMED CORPORATION’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on IRADIMED CORPORATION’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

IRADIMED CORPORATION’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about IRADIMED CORPORATION (IRMD) by visiting AAII Stock Evaluator.

Relative Price Strength of IRADIMED CORPORATION

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, IRADIMED CORPORATION has a weighted four-quarter relative price strength of 10.34%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how IRADIMED CORPORATION is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

IRADIMED CORPORATION Stock Price: Bottom Line

As of July 31, 2026, IRADIMED CORPORATION’s stock price is $93.730, which is down 1.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like IRADIMED CORPORATION stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.